Any prior treatment with any investigational drug within the preceding 4 weeks
Use of any investigational drug within the past 4 weeks
Prior treatment with any investigational drug within the preceding 2 weeks
Prior treatment with any investigational drug within the preceding 2 weeks
Have received prior treatment with any investigational drug within 4 weeks prior to dose assignment
Prior treatment with any investigational drug within the preceding 4 weeks
Participation in any investigational drug study within 4 weeks preceding enrollment
Has received treatment with any investigational drug in the previous 4 weeks
Investigational drug therapy outside of this trial during or within 3 weeks prior to C1D1.
The patient has received any investigational drug within the past 4 weeks
Taken an investigational drug within 4 weeks prior to study drug administration or plans to take an investigational agent during the study
Treatment with any, investigational therapy within the 4 weeks prior to the initiation of study drug administration
Investigational drug therapy outside of this trial during or within 4 weeks of first study treatment
No investigational therapy within four weeks of the first dose of study drug.
Exposure to any investigational drug or placebo within 4 weeks of enrollment
Another investigational drug within 4 weeks of study drug administration
Treatment with an investigational anti-cancer study drug within 4 weeks prior to study drug administration date.
Administration of any investigational drug within 4 weeks prior to the first dose of study treatment
Exposure to any investigational drug within 4 weeks of study drug administration
Patients must not have received an investigational anti-cancer drug within two weeks of start of protocol treatment
Has received an investigational therapeutic drug within the last 4 weeks prior to start of study treatment, or is scheduled to receive one during the treatment period
Participation in another investigational drug study in the prior 4 weeks
Any investigational drug within 4 weeks
Prior treatment with any investigational drug within the preceding 4 weeks
Planned treatment, or treatment with any investigational drug within 4 weeks prior to screening.
No investigational therapy within 4 weeks of first dose of study drug
Participation in any investigational drug study within 4 weeks preceding the start of study treatment
Treated with any investigational drug within 2 weeks of the first dose of study treatment.
Prior treatment with any investigational drug within the preceding 4 weeks prior to starting study drug
Any investigational drug < 6 weeks prior to the first dose of study drug or not recovered from effects of prior investigational agent
Another investigational drug within 4 weeks of study drug administration
Participation in any investigational drug study within 4 weeks preceding the start of study treatment; patients are not permitted to participate in another investigational drug study while being treated on this protocol
Exposure to any investigational drug within 4 weeks of study drug administration
Received other cancer treatment or investigational drug within 4 weeks prior to screening
Participation in another investigational drug study in the prior 8 weeks
Participation in any investigational drug study within 4 weeks preceding the start of study treatment
Prior chemotherapy, cancer immunosuppressive therapy, or other investigational agents within 4 weeks before first dose of study drug.
Participation in any investigational drug study within 4 weeks preceding the start of study treatment
Prior treatment with any investigational drug within the preceding 4 weeks
Treatment with any investigational drug within 2 weeks before first administration of present trial drug.
Participation in any investigational drug study within 4 weeks preceding the start of study treatment
Prior treatment with any investigational drug within the preceding 4 weeks
Individuals who have received any investigational drug within 4 weeks
Participation in any investigational drug study within 4 weeks preceding the start of study treatment
Have received prior cancer or other investigational therapy within 2 weeks prior to the first administration of study drug
Treatment with systemic investigational drug within 4 weeks or topical investigational drug within 7 days of study start
Investigational drug other than NEOD001 within 4 weeks
Use of any investigational drug within 4 weeks
No investigational drug within 4 weeks of starting study treatment.
Use of any investigational drug or treatment within 4 weeks prior to enrollment
Treatment with any investigational drug within 6 weeks of first dose of mirvetuximab soravtansine
Participation in any investigational drug study within 4 weeks preceding the start of study treatment
Exposure to another investigational drug within 3 weeks prior to start of study treatment.
Discontinued prior systemic treatment or any investigational drug for at least 2 weeks (14 days) or for at least 3 weeks for IV anti-cancer drugs, prior to the study randomization
Treatment with an investigational drug within 3 weeks prior to the first dose of study drug
Participation in a study of an investigational drug within 4 weeks prior to the planned first day of study drug administration
Prior treatment with any investigational drug within the preceding 2 weeks
Received prior cancer or other investigational therapy within 2 weeks prior to the first administration of study drug;
Treatment with another investigational drug within the past four weeks before start of therapy or concomitantly with this trial.
Prior treatment with any investigational drug within the preceding 4 weeks
Use of any investigational drug within the past 4 weeks before start of study medication or concomitantly with this study except for investigational immune-stimulatory therapy (e.g. checkpoint-regulator targeted treatment). The minimum washout period should be 8 weeks before starting the study medication.
Participation in any investigational drug study within 4 weeks preceding the start of study treatment
Treatment with an investigational anti-cancer study drug within 3 weeks prior to study drug administration date
